{"name":"Rznomics, Inc.","slug":"rznomics-inc","ticker":"","exchange":"","domain":"","description":"Rznomics, Inc. is a biotechnology company focused on developing innovative therapies for unmet medical needs. The company's lead candidate, RZ-001, is currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RZ-001","genericName":"RZ-001","slug":"rz-001","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"RZ-001","genericName":"RZ-001","slug":"rz-001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBCTGFPRjhTakJZUi01RF9jSkJyX0ZXT0x3MWN0Q3N5TjN0U0Jid2RUclFGaHliTUFkc3RySEdkSGFPel9BaU1NOWJjUnFVN05leWl1MVJQU0RPNENCanpqXzRlWm81cE9kcXRyRi1R0gFyQVVfeXFMTkJBTXIxc2FZeW92TlVjaHBPTi1mZGFYNWFHbWpHZ05RTlJYOS1LV0ZMMWJkVmF3S2l4VVdXd0U3WDBOc3FfUGNtdXFyeGlRTlFpTlhSdWxzQk5YdmNiT25EaUVDSXBrcTI0bWNCTE9BOWdn?oc=5","date":"2026-02-19","type":"pipeline","source":"koreabiomed.com","summary":"Rznomics gets funding from Eli Lilly for researching hereditary hearing loss treatment - koreabiomed.com","headline":"Rznomics gets funding from Eli Lilly for researching hereditary hearing loss treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1UeEp3eTQ0ZXBZUlRFSEhrc1VpS0QyOGV2dEpVS1ZYMVJIT3kyNm0xNDdhQjU2cEtTd0xHWnF3MHdyNjBKd3k4eXR6cll0OXduaHYwTHZnQUpMeXNac3E0N2t4TDYxdi1pVTFxV3ln?oc=5","date":"2025-12-23","type":"pipeline","source":"팜이데일리","summary":"Rznomics extends rally, shares up 576% from IPO price[K-Bio Pulse] - 팜이데일리","headline":"Rznomics extends rally, shares up 576% from IPO price[K-Bio Pulse] - 팜이데일리","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5YN09mNTlhbWt1VXdiMjlVeEl5azkzcWtPU2oydzNSV0ZZMjJ6SzJXa0dmQXBacTNQaEJFNFZsc0Y2NG1MTGpBR3dYRmg3RGtjb2hnejVBNlJLZnJaSG5Wa3JEbnBwUlZuN2NIVUpB?oc=5","date":"2025-11-12","type":"deal","source":"KED Global","summary":"ABL Bio lands $2.6 bn Eli Lilly deal, capping record year for S.Korean biotech exports - KED Global","headline":"ABL Bio lands $2.6 bn Eli Lilly deal, capping record year for S.Korean biotech exports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVlo0UlJ3YmZfN1Foa3J1end3NHMyb0hXekVqQ0h3X2l6SVFwcnZlQkdGNXhqZzFGZWMwTUxxZkU5QTBZcUNGNDRheUIxWWVkMkZySm9qMXU0bnVadmVaMGRHdEF6RjU3SDJWM0VqNWQyaUJlUkNWY3puLUNIb1pSbk1HZEtBZFNkdmlkN1EzTmM4bjFkNkFpRHc0NjlZRnpWMDE1VGhkUzg?oc=5","date":"2025-06-17","type":"deal","source":"BioWorld News","summary":"Korea biotech roundup: four financings, six R&D deals mid-June - BioWorld News","headline":"Korea biotech roundup: four financings, six R&D deals mid-June","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOZC1jbUhHbHNlU1dxY1ctSVkwRF9XOXdiM2FaZ3hzZ2VLQzgyS2J4RUdzNmdydnItSjBoM0I4aWFQdV9ybi1FSWpsbjdxa1JlS0tyQXh4cWNPQTNudVlubHBlTzlQUWIxQUg4WmFzWE0tN3c5WXNxdmNrdlVwT0g3N0xHRjZlTThoeGwyUUFBaG5idVZ4MzBxSjN4QzFQRTNjeE8yUWdZdw?oc=5","date":"2025-05-20","type":"pipeline","source":"BioWorld News","summary":"Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug - BioWorld News","headline":"Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQMW44Smxibmp4amdtbnVWUVhVV1lGMnRrVHVJemI0eENCeWtwbHFvb21GSDMtaVFvQzZ2Z25KTTZvbFhOeGFfcDlHa1VQWklKV0gyX21oaDIyVXhLOVBGSm1XMjhfZm5ob283UlpVVUxfSVNpbVlKT001ZUtORE4zMmFLQzBwTnJobFcxMXFoYmg0aVBnUVFOUjRtOTFzcDhEVzc2d0dn?oc=5","date":"2025-05-16","type":"deal","source":"Pharmaceutical Technology","summary":"Eli Lilly strikes $1.3bn gene therapy deal with Rznomics - Pharmaceutical Technology","headline":"Eli Lilly strikes $1.3bn gene therapy deal with Rznomics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPQjczcVdvNU11MXYyaU5QNHlMOXQwcE1XYjVXaGtWN1QtVUE5UGdsV1c0V1RoLUlwRFhMTVpyOWRrNElFSjRTMENzUENzeEtvMnhUSUNqNjN6OWpmbjIxMkNaQWZublB3MTh3cFVDYlZSY005MklseUZGd1JQN3R2OGV3bVM3Zkl1NUVSTDNXOGVtWWFHeUZFcFcyNXR3dw?oc=5","date":"2025-05-16","type":"pipeline","source":"Contract Pharma","summary":"Rznomics & Eli Lilly Enter Global Licensing Agreement - Contract Pharma","headline":"Rznomics & Eli Lilly Enter Global Licensing Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBXcEluZWczNmx3SmxLY0ZwTXo2MFBjVlgxcktGYUg4U2VueGRSRU9fREs1Q3J0dVY2SkNaY3hkTV9IZ1NYczVLRGhOWVk2TTEtMmoybktHREFuRkZ0dVlyOFQxdEVra3RZTHpIVkZR?oc=5","date":"2025-05-16","type":"deal","source":"KED Global","summary":"South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly - KED Global","headline":"South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQa285ME1HYXgwSEh3Y2J5cXBDNE5EVUJxanhyZ0I2b3JiSnNLaVM3OE03SENtaHJVYjRkYXZKajBhNGdKRlM4ODB4RmhVWXR1VE1BZExweWtFSnNlclNRaHpHRnRHNmVheXdnOGgtSkJiVHkzVlpOclZzc0FUb2oxQTNWdm9qNTQ5YW1zbDVILXZKN2VrMlhzZnA3YUZhS1Fw?oc=5","date":"2025-05-16","type":"pipeline","source":"Fierce Biotech","summary":"Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact - Fierce Biotech","headline":"Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQSFR2cEp2UnYtUDRyOTkzbld5cjlaWW5Va2dnck52dXFCdGpBbkVya0kyX3d4YWVzeGZtMFlzQlRzNXNzZU5tdHdzZ0ZKaTN6TXlrQXVJVTBNaUpkMm1ESzJIZmtUOVVURVRKb2lJbDctVnVuSTN0OXktU3gtUW8wMHBXRWhUa094QXdRZEpCd3hNdw?oc=5","date":"2025-05-15","type":"pipeline","source":"Yahoo Finance","summary":"Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics - Yahoo Finance","headline":"Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBwRllOZTYyR1hoZHRwQTZfbWVJUnBMWk0tQVpmMTZtOWF3dmlyT3RtcVJqMVo4TXFzUk5FbU5LWE9VaHkxSVkzVW9iUzQxVVVXeVJkWkZDS3kyODZvcnFoZTB6ZlRncGdrNWhReEhPUmxzYjhLamc?oc=5","date":"2025-02-18","type":"regulatory","source":"Pharmaceutical Technology","summary":"FDA grants fast track status to Rznomics' RZ-001 drug for HCC - Pharmaceutical Technology","headline":"FDA grants fast track status to Rznomics' RZ-001 drug for HCC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNTUxGbEJfTjFBS2dmOEJJMUh6LWtrejF5dEo1VXRrNDdsWU9GOUIwOUxONVJPU2prZ0hrRnBkRHhQQ2xpSmhtaGg0YUctMXF4bGtxOGpCdnFUNDNQdi1OQmNIUVdzRDYycnpfVHBHU2YzVE1CMGZrdE9MRk1tWDBrNHF1NWhDRlFqamozOXlRY1Mtb3ViOTJ2MWdfT0lLX1FNX3JMREJB?oc=5","date":"2023-01-18","type":"pipeline","source":"Fierce Pharma","summary":"Charles River inks gene therapy development and manufacturing pact with South Korean biopharma - Fierce Pharma","headline":"Charles River inks gene therapy development and manufacturing pact with South Korean biopharma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}